MEF2D通过CD70-CD27信号调节T细胞功能,并在肝细胞癌中促进免疫逃避
Fanhua Kong1, Liqing Wang2, Zhongshan Lu1
1Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Clinical Research Center for Natural Polymer Biological Liver, Hubei Engineering Center of Natural Polymer-Based Medical Materials, Wuhan, Hubei, China.
肝细胞癌 (HCC) 避免了免疫系统的攻击. MEF2D调节CD70,影响T细胞免疫力,这表明肝癌的新治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因.
- 免疫逃避是HCC治疗的一个主要挑战.
研究的目的:
- 调查MEF2D在HCC免疫逃避中的作用.
- 阐明MEF2D影响抗瘤免疫力的机制.
主要方法:
- 在HCC细胞系中进行MEF2D敲击.
- 在HCC组织和细胞上进行RNA测序,西斑和免疫组织化学.
- 染色体免疫沉以评估MEF2D与CD70促进体的结合.
- 在体内研究使用合成基因小鼠模型.
- 用于T细胞分析的流细胞计.
主要成果:
- 在HCC中,MEF2D的淘汰导致了较小的瘤,T细胞激活的增加和调节性T细胞 (Treg) 功能的减少.
- MEF2D直接与CD70基因促进体结合并激活,通过p300乙化增强.
- 在小鼠中,CD70阻断损害了Treg功能,并增强了抗瘤免疫力.
结论:
- MEF2D通过上调CD70表达和激活CD70-CD27轴来促进HCC免疫逃避.
- 向MEF2D-CD70通路可能会提高肝癌免疫疗法的疗效.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
相关概念视频
Master Transcription Regulators
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Abnormal Proliferation
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
